Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients - Trial NCT06404697
Access comprehensive clinical trial information for NCT06404697 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ruijin Hospital and is currently Recruiting. The study focuses on Breast Cancer. Target enrollment is 24 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Ruijin Hospital
Timeline & Enrollment
Phase 2
May 01, 2024
Apr 01, 2030
Primary Outcome
2-year recurrence-free survival
Summary
cN3c breast cancer with ipsilateral supraclavicular (SCV) lymph nodal (SCLN) metastasis is
 known to have a dismal prognosis. Currently, the combined-modality therapy consisting of
 primary systemic therapy (PST), subsequent local and/or systemic therapy based on response is
 the standard of care. However, the value of giving radiotherapy (RT) boost to SCV region
 remains uncertain in cN3c patients. This study aimed to assess the efficacy and safety of RT
 boost to the SCV area in high-risk cN3c breast cancer patients based on nodal response
 following PST.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06404697
Non-Device Trial